Abstract
Bisphosphonates (BP) are dominant drug in postmenopausal osteoporosis treatment. Positive results are supported by evidence-based studies.
The increasing discussion about over-suppression of bone metabolism, resulting into microdamages and microcracks started development of newer forms of BP with prolonged intervals between dosing. Intravenous BPs are useful in patients with gastrointestinal diseases